Aarey Drugs & Pharmaceuticals Limited
NSE: AAREYDRUGS
NSE
68.18
-1.40 (-2.01%)
Prev Close
69.58
Open Price
68.18
Volume
27,477
Today Low / High
68.18 / 68.3
52 WK Low / High
32.85 / 74.8
Range
65 - 72
Currently, the stock is trading on the National Stock Exchange (NSE). The stock price stands at 68.18, with a change of -1.4 (-2.01207%). The expected target range on the NSE is between 65 - 72. The stock is experiencing a downward trend on the NSE. Investors should be cautious as the price is currently declining.
04 Jul
72.42
0.00%
03 Jul
69.75
1.79%
02 Jul
70.74
-0.62%
01 Jul
69.36
0.00%
30 Jun
66.30
2.56%
27 Jun
65.40
3.46%
26 Jun
63.75
1.57%
25 Jun
64.25
-3.19%
24 Jun
61.00
1.57%
23 Jun
57.00
4.89%
20 Jun
54.40
4.69%
19 Jun
54.60
-0.22%
18 Jun
56.35
-3.21%
17 Jun
57.50
-2.17%
Aarey Drugs & Pharmaceuticals Limited Graph
Aarey Drugs & Pharmaceuticals Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Aarey Drugs & Pharmaceuticals Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 68.18, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 68.18 | 68.86 | 61.98 - 75.75 |
| 69.54 | 55.63 - 83.45 | ||
| 70.23 | 49.16 - 91.29 | ||
| Bearish Scenario | 68.18 | 67.50 | 60.75 - 74.25 |
| 66.82 | 53.45 - 80.18 | ||
| 66.13 | 46.29 - 85.97 |
Overview of Aarey Drugs & Pharmaceuticals Limited
ISIN
INE198H01019
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
69,899
Market Cap
2,053,418,406
Last Dividend
0
Official Website
IPO Date
2021-08-06
DCF Diff
110.01
DCF
-39
Financial Ratios Every Investor Needs
Stock Dividend of AAREYDRUGS
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2018-12-13 | December 13, 18 | 0.1 | 0.1 | 2018-12-14 | 2018-12-30 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 473.94 Cr | 464.81 Cr | 9.13 Cr | 0.0193 | 0.00 Cr | 0.00 Cr | 0.31 Cr | 4.02 Cr | 1.43 | 12.06 Cr | 0.0085 |
| 2024-03-31 | 395.10 Cr | 381.90 Cr | 13.20 Cr | 0.0334 | 0.00 Cr | 0.42 Cr | 2.82 Cr | 4.68 Cr | 1.84 | 11.42 Cr | 0.0119 |
| 2023-03-31 | 414.25 Cr | 403.84 Cr | 10.41 Cr | 0.0251 | 0.00 Cr | 0.88 Cr | 6.69 Cr | 3.77 Cr | 1.49 | 8.27 Cr | 0.0091 |
| 2022-03-31 | 491.61 Cr | 472.06 Cr | 19.54 Cr | 0.0398 | 0.00 Cr | 0.61 Cr | 10.03 Cr | 6.55 Cr | 2.72 | 12.01 Cr | 0.0133 |
| 2021-03-31 | 347.89 Cr | 337.79 Cr | 10.10 Cr | 0.0290 | 0.00 Cr | 0.32 Cr | 8.23 Cr | 6.51 Cr | 2.79 | 9.15 Cr | 0.0187 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 1.47 Cr | 238.27 Cr | 99.79 Cr | 138.4805 Cr | 34.86 Cr | 33.38 Cr | 45.48 Cr | 16.22 Cr | 0.00 Cr | 0.00 Cr | 8.76 Cr | 96.8804 Cr |
| 2024-03-31 | 1.59 Cr | 303.29 Cr | 170.52 Cr | 132.7734 Cr | 31.35 Cr | 29.76 Cr | 71.99 Cr | 12.96 Cr | 0.00 Cr | 0.00 Cr | 2.09 Cr | 166.5469 Cr |
| 2023-03-31 | 0.71 Cr | 291.32 Cr | 173.91 Cr | 117.4138 Cr | 37.72 Cr | 37.01 Cr | 28.82 Cr | 13.94 Cr | 5.28 Cr | 0.00 Cr | 0.41 Cr | 168.1349 Cr |
| 2022-03-31 | 0.19 Cr | 245.17 Cr | 131.53 Cr | 113.6373 Cr | 14.16 Cr | 13.97 Cr | 13.68 Cr | 14.47 Cr | 5.23 Cr | -3.34 Cr | 2.80 Cr | 130.0762 Cr |
| 2021-03-31 | 0.64 Cr | 233.04 Cr | 134.18 Cr | 98.8605 Cr | 18.02 Cr | 17.38 Cr | 18.46 Cr | 14.26 Cr | 4.25 Cr | 0.00 Cr | 0.40 Cr | 132.6120 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 0.8948 Cr | -5.9394 Cr | 4.9237 Cr | -4.3096 Cr | 0.0000 Cr | 1.4733 Cr | -5.2044 Cr | 4.0239 Cr | 3.2337 Cr | 0.0000 Cr | -10.8045 Cr |
| 2024-03-31 | -2.9938 Cr | -1.7023 Cr | 5.5848 Cr | -3.7161 Cr | 0.8886 Cr | 1.5944 Cr | -0.7223 Cr | 4.6837 Cr | -1.1362 Cr | 0.0000 Cr | -5.8566 Cr |
| 2023-03-31 | -1.2811 Cr | 0.4410 Cr | 1.3540 Cr | -2.3251 Cr | 0.5139 Cr | 0.7058 Cr | -1.0440 Cr | 6.0151 Cr | 4.2211 Cr | 0.0000 Cr | -15.1352 Cr |
| 2022-03-31 | -4.4930 Cr | -2.1967 Cr | 6.2319 Cr | -6.6943 Cr | -0.4578 Cr | 0.1919 Cr | -2.2013 Cr | 10.0271 Cr | 0.0000 Cr | 0.0000 Cr | 4.7767 Cr |
| 2021-03-31 | 5.4770 Cr | -2.8793 Cr | -2.4507 Cr | 2.5977 Cr | 0.1470 Cr | 0.6497 Cr | -2.8793 Cr | 8.3014 Cr | -0.0191 Cr | 0.0000 Cr | -1.4646 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 108.10 Cr | 108.02 Cr | 0.08 Cr | 0.0007 | -3.43 Cr | 0.47 Cr | 0.02 | 2.69 Cr | 0.0043 |
| 2024-12-31 | 133.79 Cr | 130.39 Cr | 3.40 Cr | 0.0254 | 1.62 Cr | 0.72 Cr | 0.26 | 2.88 Cr | 0.0054 |
| 2024-09-30 | 105.14 Cr | 98.90 Cr | 6.24 Cr | 0.0594 | 3.23 Cr | 1.60 Cr | 0.57 | 3.74 Cr | 0.0152 |
| 2024-06-30 | 126.91 Cr | 123.59 Cr | 3.32 Cr | 0.0261 | 2.58 Cr | 1.24 Cr | 0.44 | 2.75 Cr | 0.0098 |
| 2024-03-31 | 210.35 Cr | 206.75 Cr | 3.60 Cr | 0.0171 | -1.84 Cr | 2.15 Cr | 0.77 | 3.70 Cr | 0.0102 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 1.47 Cr | 0.00 Cr | 1.47 Cr | 159.55 Cr | 45.48 Cr | 213.28 Cr | 16.22 Cr | 238.27 Cr | 99.79 Cr |
| 2024-12-31 | 0.00 Cr | 0.00 Cr | 1.49 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -135.59 Cr |
| 2024-09-30 | 1.49 Cr | 0.00 Cr | 1.49 Cr | 0.00 Cr | 29.84 Cr | 251.35 Cr | 12.99 Cr | 274.53 Cr | 138.94 Cr |
| 2024-06-30 | 0.00 Cr | 0.00 Cr | 2.89 Cr | 0.00 Cr | 0.00 Cr | 2.89 Cr | 0.00 Cr | 0.00 Cr | -132.77 Cr |
| 2024-03-31 | 1.59 Cr | 1.30 Cr | 1.59 Cr | 200.85 Cr | 34.68 Cr | 282.60 Cr | 14.66 Cr | 304.99 Cr | 172.22 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2024-12-31 | 0.72 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-09-30 | 1.60 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-06-30 | 1.24 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-03-31 | 2.15 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-12-31 | 1.02 Cr | 0.94 Cr | 0.00 Cr | 0.00 Cr | 0.94 Cr | 2.11 Cr | 1.17 Cr | 0.00 Cr | 0.94 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| No split history data available. | ||
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,727.50 | ₹4,144,756,200,000.00 | ₹3,332,399.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,790.00 | ₹1,802,534,510,000.00 | ₹132,232.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹3,439.60 | ₹1,164,115,422,000.00 | ₹494,063.00 |
| Mankind Pharma Limited | MANKIND | ₹2,651.00 | ₹1,094,143,942,760.00 | ₹597,220.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,260.90 | ₹1,049,169,344,166.00 | ₹1,183,510.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹967.65 | ₹973,678,459,500.00 | ₹553,261.00 |
| Lupin Limited | LUPIN | ₹1,950.70 | ₹890,915,901,200.00 | ₹989,769.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,152.00 | ₹669,083,904,000.00 | ₹847,057.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹2,226.10 | ₹628,207,646,100.00 | ₹1,665,996.00 |
| Alkem Laboratories Limited | ALKEM | ₹4,933.20 | ₹589,838,058,000.00 | ₹225,900.00 |
| Laurus Labs Limited | LAURUSLABS | ₹827.05 | ₹445,989,193,650.00 | ₹2,079,496.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Cohance Lifesciences Limited | COHANCE | ₹1,056.65 | ₹404,239,429,003.00 | ₹509,252.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,470.90 | ₹373,173,213,600.00 | ₹352,054.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,697.70 | ₹336,975,102,400.00 | ₹391,905.00 |
| Piramal Enterprises Limited | PEL | ₹1,323.30 | ₹299,962,997,400.00 | ₹4,378,654.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,828.00 | ₹297,011,612,000.00 | ₹915,293.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,650.10 | ₹257,512,955,900.00 | ₹382,076.00 |
| Eris Lifesciences Limited | ERIS | ₹1,754.30 | ₹238,930,397,100.00 | ₹62,993.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹9,160.00 | ₹229,000,000,000.00 | ₹106,684.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹1,030.50 | ₹202,558,171,500.00 | ₹176,478.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹15,273.00 | ₹195,951,062,700.00 | ₹708,175.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹1,202.60 | ₹191,551,330,600.00 | ₹219,891.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹1,011.60 | ₹181,187,676,000.00 | ₹1,566,502.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹2,077.00 | ₹157,876,300,900.00 | ₹85,573.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Granules India Limited | GRANULES | ₹491.75 | ₹119,320,187,000.00 | ₹530,605.00 |
| Procter & Gamble Health Limited | PGHL | ₹5,859.00 | ₹97,255,884,600.00 | ₹7,510.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹892.50 | ₹87,278,378,250.00 | ₹53,870.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹944.70 | ₹85,622,525,514.00 | ₹399,854.00 |
| Strides Pharma Science Limited | STAR | ₹906.20 | ₹83,517,838,740.00 | ₹423,182.00 |
| FDC Limited | FDC | ₹506.75 | ₹82,503,967,500.00 | ₹246,575.00 |
| Suven Life Sciences Limited | SUVEN | ₹296.60 | ₹64,680,748,400.00 | ₹267,211.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹162.25 | ₹52,653,694,500.00 | ₹541,111.00 |
| Innova Captab Limited | INNOVACAP | ₹907.95 | ₹51,957,375,194.00 | ₹53,071.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹530.30 | ₹48,400,481,000.00 | ₹8,303,349.00 |
| Sequent Scientific Limited | SEQUENT | ₹181.37 | ₹45,397,817,850.00 | ₹819,841.00 |
| Hikal Limited | HIKAL | ₹347.80 | ₹42,884,087,800.00 | ₹221,871.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹2,557.00 | ₹42,290,223,000.00 | ₹54,612.00 |
| Unichem Laboratories Limited | UNICHEMLAB | ₹598.00 | ₹42,102,668,400.00 | ₹135,253.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹739.95 | ₹37,529,598,045.00 | ₹194,616.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹371.40 | ₹37,243,249,200.00 | ₹103,451.00 |
| Morepen Laboratories Limited | MOREPENLAB | ₹63.02 | ₹34,532,061,080.00 | ₹1,731,372.00 |
| Solara Active Pharma Sciences Limited | SOLARA | ₹692.35 | ₹33,338,729,550.00 | ₹214,128.00 |
| Alembic Limited | ALEMBICLTD | ₹119.89 | ₹30,785,593,860.00 | ₹1,073,087.00 |
| Indoco Remedies Limited | INDOCO | ₹331.15 | ₹30,547,892,085.00 | ₹64,236.00 |
| IOL Chemicals and Pharmaceuticals Limited | IOLCP | ₹93.57 | ₹27,465,321,390.00 | ₹989,945.00 |
Key Executives
Chief Accountant
Mr. A. S. Kathawala
Gender: male
Year Born: 1976
Company Secretary & Compliance Officer
Mr. Kailash Chand Jethlia
Gender: male
Year Born:
Chairman & MD
Mr. Mihir Rajesh Ghatalia B.E
Gender: male
Year Born: 1983
Chief Financial Officer
Ms. Mira Mihir Ghatalia
Gender: female
Year Born:
Executive Director
Mr. Nimit Rajesh Ghatalia
Gender: male
Year Born: 1996
FAQs about Aarey Drugs & Pharmaceuticals Limited
Who is the CEO of the company?
The CEO is Mihir Rajesh Ghatalia.
What is the current market price of the stock?
The current price is ₹72.42.
What is the 52-week price range?
The range is ₹32.85-74.8.
What is the market capitalization of the company?
The market capitalization is ₹205.34 crores.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 50.49.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Aarey Drugs & Pharmaceuticals Limited (ISIN: INE198H01019) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹205.34 crores and an average daily volume of 69,899 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹0.